.Pharmacolibrary.Drugs.ATC.J.J01FA16

Information

Solithromycin is a fluoroketolide antibiotic of the macrolide class. It was developed for the treatment of community-acquired bacterial pneumonia and other infections caused by susceptible bacteria. As of 2024, solithromycin is not approved for clinical use in the United States or Europe, with development halted after regulatory concerns about liver safety.

Pharmacokinetics

Pharmacokinetic parameters in healthy adult volunteers after oral administration.

References

1. Gonzalez, D, et al., & Cohen-Wolkowiez, M (2018). Population Pharmacokinetics and Safety of Solithromycin following Intravenous and Oral Administration in Infants, Children, and Adolescents. Antimicrobial agents and chemotherapy 62(8) –. DOI:10.1128/AAC.00692-18 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29891609

2. Zhanel, GG, et al., & Karlowsky, JA (2016). Solithromycin: A Novel Fluoroketolide for the Treatment of Community-Acquired Bacterial Pneumonia. Drugs 76(18) 1737–1757. DOI:10.1007/s40265-016-0667-z PUBMED:https://pubmed.ncbi.nlm.nih.gov/27909995

3. Viasus, D, et al., & Carratalà, J (2017). Solithromycin for the treatment of community-acquired bacterial pneumonia. Expert review of respiratory medicine 11(1) 5–12. DOI:10.1080/17476348.2017.1249852 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27753516

Revisions

• 06/2025 initial generated model